Literature DB >> 21054148

Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma.

Jens Hasskarl1, Gabriele Ihorst, David De Pasquale, Percy Schröttner, Alf Zerweck, Ralph Wäsch, Monika Engelhardt.   

Abstract

Multiple myeloma (MM) has been suggested to be associated with different neoplasms. Of 589 consecutive patients with MM, 59 (10%) had different neoplasms: solid tumors in 78% and hematological neoplasms in 22%. Different neoplasms were separated into those emerging prior or synchronously (p/s; n = 41) versus subsequently after the MM (n = 18). The rate of different neoplasms at the time of MM diagnosis was estimated as 6.6%, and estimated different neoplasm rates at 2, 5, and 10 years were 7.8%, 10.3%, and 11.6%, respectively. Patients with MM with p/s different neoplasms showed a hazard ratio (HR) for impaired overall survival of 1.2 (95% CI 0.8-2.0), whereas in those with subsequent neoplasms the HR was 2.5 (95% CI 1.4-4.4). This demonstrates that (1) p/s are more frequent compared with subsequent different neoplasms, and (2) the prognosis is more impaired with subsequent different neoplasms. Age ≥60 years was a confounding covariable with a HR of 2.021 (95% CI 1.6-2.6).

Entities:  

Mesh:

Year:  2010        PMID: 21054148     DOI: 10.3109/10428194.2010.529207

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  32 in total

Review 1.  Second malignancies after multiple myeloma: from 1960s to 2010s.

Authors:  Anish Thomas; Sham Mailankody; Neha Korde; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2012-02-06       Impact factor: 22.113

2.  Increased incidence of bladder cancer, lymphoid leukaemia, and myeloma in a cohort of Queensland melanoma families.

Authors:  Jazlyn Read; Judith Symmons; Jane M Palmer; Grant W Montgomery; Nicholas G Martin; Nicholas K Hayward
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

Review 3.  Second malignancies in multiple myeloma; emerging patterns and future directions.

Authors:  Kylee Maclachlan; Benjamin Diamond; Francesco Maura; Jens Hillengass; Ingemar Turesson; C Ola Landgren; Dickran Kazandjian
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-11       Impact factor: 3.020

4.  Concomitant Presence of Two Distinct Clones of Chronic Lymphocytic Leukemia and Plasma Cell Myeloma in a Patient.

Authors:  Sabina Langer; Meenal Mehta; Amrita Saraf; Aastha Gupta; Keyur Pipliya; Atul Kakar; Manorama Bhargava
Journal:  Indian J Hematol Blood Transfus       Date:  2015-03-01       Impact factor: 0.900

5.  Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.

Authors:  Monika Engelhardt; Sandra Maria Dold; Gabriele Ihorst; Alexander Zober; Mandy Möller; Heike Reinhardt; Stefanie Hieke; Martin Schumacher; Ralph Wäsch
Journal:  Haematologica       Date:  2016-06-16       Impact factor: 9.941

6.  The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.

Authors:  Gudbjörg Jonsdottir; Sigrún H Lund; Magnus Björkholm; Ingemar Turesson; Malin Hultcrantz; Anna Porwit; Yogesh S Jethava; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-11-22

7.  Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma.

Authors:  O Landgren; W Ma; R A Kyle; S V Rajkumar; N Korde; M Albitar
Journal:  Leukemia       Date:  2011-09-16       Impact factor: 11.528

8.  Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).

Authors:  Sham Mailankody; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Neha Korde; Magnus Bjorkholm; Lynn R Goldin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

9.  New cancers after autotransplantations for multiple myeloma.

Authors:  Anuj Mahindra; Girindra Raval; Paulette Mehta; Ruta Brazauskas; Mei-Jie Zhang; Xiaobo Zhong; Jennifer M Bird; César O Freytes; Gregory A Hale; Roger Herzig; Leona A Holmberg; Rammurti T Kamble; Shaji Kumar; Hillard M Lazarus; Navneet S Majhail; David I Marks; Jan S Moreb; Richard Olsson; Wael Saber; Bipin N Savani; Gary J Schiller; Jason Tay; Dan T Vogl; Edmund K Waller; Peter H Wiernik; Baldeep Wirk; Sagar Lonial; Amrita Y Krishnan; Angela Dispenzieri; Nancy A Brandenburg; Robert Peter Gale; Parameswaran N Hari
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-31       Impact factor: 5.742

10.  European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

Authors:  Monika Engelhardt; Evangelos Terpos; Martina Kleber; Francesca Gay; Ralph Wäsch; Gareth Morgan; Michele Cavo; Niels van de Donk; Andreas Beilhack; Benedetto Bruno; Hans Erik Johnsen; Roman Hajek; Christoph Driessen; Heinz Ludwig; Meral Beksac; Mario Boccadoro; Christian Straka; Sara Brighen; Martin Gramatzki; Alessandra Larocca; Henk Lokhorst; Valeria Magarotto; Fortunato Morabito; Meletios A Dimopoulos; Hermann Einsele; Pieter Sonneveld; Antonio Palumbo
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.